Home > > Global Direct to Consumer Genetic Testing Market Report
The Direct to Consumer Genetic Testing market was valued at $282,434.8 Million in 2023, and is projected to reach $342,889.0 Million by 2030 growing at a CAGR of 2.86% from 2024 to 2030. Clinical Chemistry segment is expected to be the highest contributor to this market, with $126,244.7 Million in 2023, and is anticipated to reach $153,499.9 Million by 2030, registering a CAGR of 2.88%. Human & Tumor Genetics segment is anticipated to reach $83,299.4 Million by 2030 with the highest CAGR of 3.00%. Clinical Chemistry and Human & Tumor Genetics segments collectively expected to account for about 68.8% share of the Direct to Consumer Genetic Testing market in 2023, with the former constituting around 44.7% share. Human & Tumor Genetics and Medical Microbiology & Cytology segments are expected to witness significant growth rates at a CAGR of 3.00% and 2.93% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 44.0% in the overall Direct to Consumer Genetic Testing market in 2023, and is anticipated to reach 44.3% by 2030. Test Type Human & Tumor Genetics Clinical Chemistry Medical Microbiology & Cytology Other Test Types Service provider Hospital-based Laboratories Stand-alone Laboratories Clinic-based Laboratories BY REGION North America U.s. Canada Mexico Europe Germany France U.k. Italy Spain Russia Rest of Europe Asia China India Japan Australia Rest of Asia Middle East & Africa Brazil South Africa GCC Rest of MENA